Biogen gains on new Eli Lilly Alzheimer’s data, as beta-amyloid hypothesis ‘lives to see another day’ By: MarketWatch December 09, 2016 at 12:55 PM EST Failed trial includes some positive results, but analysts and doctors argue about how much. Read More >> Related Stocks: AC Immune S.A. Astrazeneca Plc ADR Biogen Idec Eli Lilly Merck & Co Standard & Poors 500